SAVE THE DATE
June 23-25, 2011 in Washington, DC. For more information visit curemeso.org/symposium. Stay tuned…
Adding immunotherapy to chemotherapy plus bevacizumab shows promising benefit in survival for non-epitheliod mesothelioma patients, but not across the board
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
